SSRIs treatment did not completely restore affective state in patients with the initial clinically confirmed major depressive disorder/generalized anxiety disorder after COVID-19 disease

SSRIs treatment did not completely restore affective state in patients with the initial clinically confirmed major depressive disorder/generalized anxiety disorder after COVID-19 disease

Introduction The major clinical outcomes of COVID-19 in the brain are associated with its deleterious neurological and mental health actions. Today, there are limited findings concerning the studying of neuropsychiatric action for SARS-Cov-2 in humans after COVID-19 disease. Objectives The aim of...

Full description

Bibliographic Details
Main Authors:	J. Fedotova, Z. Bereza
Format:	Article
Language:	English
Published:	Cambridge University Press 2022-06-01
Series:	European Psychiatry
Subjects:	Covid-19 depression anxiety SSRIs pharmacotherapy
Online Access:	https://www.cambridge.org/core/product/identifier/S0924933822002796/type/journal_article

Similar Items

Efficacy and safety of agomelatine and SSRIs in the treatment of depressive disorder： a network Meta-analysis
by: Guo Huihui, et al.
Published: (2022-06-01)

Review of gastrointestinal bleeding during use of SSRIs combined with use of NSAID
by: M. Arts, et al.
Published: (2022-06-01)

Association between increased serum interleukin-8 levels and improved cognition in major depressive patients with SSRIs
by: Yuan Cai, et al.
Published: (2023-02-01)

Long and Short Duration Exposures to the Selective Serotonin Reuptake Inhibitors (SSRIs) Fluoxetine, Paroxetine and Sertraline at Environmentally Relevant Concentrations Lead to Adverse Effects on Zebrafish Behaviour and Reproduction
by: Ananda Baskaran Venkatachalam, et al.
Published: (2023-02-01)

Resting-State fMRI in Predicting Response to Treatment With SSRIs in First-Episode, Drug-Naive Patients With Major Depressive Disorder
by: Aixia Zhang, et al.
Published: (2022-02-01)

Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT
by: David Kessler, et al.
Published: (2018-11-01)

Predictive role of the degree of prospective memory impairment on treatment response to SSRIs in patients with obsessive-compulsive disorder
by: Wei Zhen, et al.
Published: (2021-08-01)

Comparisons of Serum Interleukin-8 Levels in Major Depressive Patients With Drug-Free Versus SSRIs Versus Healthy Controls
by: Zhen Hua Zhu, et al.
Published: (2022-04-01)

Anxiety disorders in adolescents
by: E. A. Korabelnikova
Published: (2018-11-01)

Response to SSRI intervention and amygdala activity during self-referential processing in major depressive disorder
by: Kymberly D. Young, et al.
Published: (2020-01-01)

Evaluating the Use of Selective Serotonin Reuptake Inhibitors (SSRIs) and Male Infertility: A Critical Retrospective Study
by: Jawza F. Alsabhan, et al.
Published: (2024-04-01)

The effect of SSRIs on Semen quality: A systematic review and meta-analysis
by: Jiarong Xu, et al.
Published: (2022-09-01)

Review of the Knowledge on Selective Serotonin Reuptake Inhibitors (SSRIs) for Depression Management by Residents and Concurrent Physicians of the Medical Clinic of 5 Hospitals in CABA
by: Gonzalo E. Barbosa Eyler, et al.
Published: (2023-09-01)

Neural Correlates of Outcome of the Psychotherapy Compared to Antidepressant Therapy in Anxiety and Depression Disorders: A Meta-Analysis
by: Navkiran Kalsi, et al.
Published: (2017-06-01)

Therapy of anxiety disorders – the problem of choosing a drug in the primary health care physician’s practice
by: Łukasz Święcicki
Published: (2015-03-01)

Depression in Major Neurodegenerative Diseases and Strokes: A Critical Review of Similarities and Differences among Neurological Disorders
by: Javier Pagonabarraga, et al.
Published: (2023-02-01)

Pathogenetically substantiated complex therapy program of anxiety disorders in internally displaced persons
by: T. Tolstaya
Published: (2021-11-01)

Selective Serotonin Reuptake Inhibitors (SSRIs) and the Risk of Congenital Heart Defects: A Meta‐Analysis of Prospective Cohort Studies
by: Shang Wang, et al.
Published: (2015-05-01)

Early effects of selective serotonin reuptake inhibitors (SSRIs) on cornea and lens density in patients with depression
by: Yalçın Karaküçük, et al.
Published: (2019-10-01)

Neurocircuitry of treatment in anxiety disorders
by: W. Tommy Baumel, et al.
Published: (2022-06-01)

Review on Surface-Modified Electrodes for the Enhanced Electrochemical Detection of Selective Serotonin Reuptake Inhibitors (SSRIs)
by: Simone C. L. Barry, et al.
Published: (2023-06-01)

Resveratrol supplementation enhanced SSRIs efficacy in premenopausal women with major depressive disorder
by: J. Fedotova, et al.
Published: (2023-03-01)

Serotonin reuptake inhibitors in Obsessive-Compulsive Disorder: antidepressant or antiobsessional agents?
by: Giuseppe Maina, et al.
Published: (2009-03-01)

The association of COMT genotype with buproprion treatment response in the treatment of major depressive disorder
by: Jay Fawver, et al.
Published: (2020-07-01)

Effect of citalopram and sertraline on the expression of miRNA- 124, 132, and 16 and their protein targets in patients with depression
by: Mahnaz Ahmadimanesh, et al.
Published: (2023-07-01)

Depersonalization - derealization syndrome: A case report
by: B Chinni Krishna, et al.
Published: (2020-01-01)

Evaluating a dimensional approach to treatment resistance in anxiety disorders: A two-year follow-up study
by: Wicher A. Bokma, et al.
Published: (2021-04-01)

A Review of the Relationship between the Endocannabinoid System and the Reduction of Depression and Anxiety
by: Ashorne Krithiesh Mahenthiran
Published: (2019-10-01)

Psychiatric Disorder Induced By Twiddler's Syndrome May Pose Treatment Challenges In Clinical Practice
by: Mohamed Tashani, et al.
Published: (2022-04-01)

Efficacy of Alfa EEG wave biofeedback in the management of anxiety
by: Pookala Bhat
Published: (2010-01-01)

Pilot of a randomised controlled trial of the selective serotonin reuptake inhibitor sertraline versus cognitive behavioural therapy for anxiety symptoms in people with generalised anxiety disorder who have failed to respond to low-intensity psychological treatments as defined by the National Institute for Health and Care Excellence guidelines
by: Marta Buszewicz, et al.
Published: (2017-08-01)

SSRIs versus other antidepressants for depressive disorder.
by: Geddes, J, et al.
Published: (2000)

The Impact of Caregiving on the Development of Major Depressive Disorder and Generalized Anxiety Disorder
by: Eve Jane Markey
Published: (2015-03-01)

Psychotherapy, pharmacotherapy, and their combination in the treatment of major depressive disorder: How well are we making use of available therapies?
by: Nădășan Ingrid Karina, et al.
Published: (2023-12-01)

Effects of Zinc Supplementation in Patients with Major Depression: A Randomized Clinical Trial
by: Elham Ranjbar, et al.
Published: (2013-06-01)

Effects of zinc supplementation in patients with major depression: a randomized clinical trial.
by: Elham Ranjbar, et al.
Published: (2013-06-01)

The impacts of the “4+7” pilot policy on the volume, expenditures, and daily cost of Serotonin-Specific Reuptake Inhibitors (SSRIs) antidepressants: A quasi-experimental study
by: Xiaotong Wen, et al.
Published: (2022-08-01)

Evaluation of depression and anxiety control in greek patients with major depressive disorder with/without generalized anxiety disorder and cardiovascular disease–pronoi study
by: P. Papanastasiou, et al.
Published: (2021-04-01)

Separation anxiety disorder among outpatients with major depressive disorder: Prevalence and clinical correlates
by: Rümeysa Yeni Elbay, et al.
Published: (2021-02-01)

Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder
by: Zastrozhin MS, et al.
Published: (2018-06-01)